Capital International Investors Increases Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)

Capital International Investors boosted its stake in shares of BeiGene, Ltd. (NASDAQ:BGNEGet Rating) by 11.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 7,055,295 shares of the company’s stock after acquiring an additional 711,396 shares during the period. Capital International Investors owned about 6.84% of BeiGene worth $1,337,378,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Vestmark Advisory Solutions Inc. raised its position in BeiGene by 27.1% during the first quarter. Vestmark Advisory Solutions Inc. now owns 1,699 shares of the company’s stock worth $320,000 after acquiring an additional 362 shares during the period. TD Asset Management Inc. raised its position in BeiGene by 0.4% during the fourth quarter. TD Asset Management Inc. now owns 24,526 shares of the company’s stock worth $6,645,000 after acquiring an additional 93 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in BeiGene by 23.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,944 shares of the company’s stock worth $3,950,000 after acquiring an additional 3,948 shares during the period. Bridgewater Associates LP raised its position in BeiGene by 67.3% during the first quarter. Bridgewater Associates LP now owns 383,818 shares of the company’s stock worth $72,388,000 after acquiring an additional 154,335 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in BeiGene by 11.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 16,071 shares of the company’s stock worth $3,031,000 after acquiring an additional 1,681 shares during the period. 51.77% of the stock is currently owned by institutional investors and hedge funds.

BeiGene Price Performance

BeiGene stock opened at $154.25 on Thursday. BeiGene, Ltd. has a 12-month low of $118.18 and a 12-month high of $426.56. The stock has a market cap of $15.98 billion, a P/E ratio of -7.55 and a beta of 0.65. The company has a 50-day moving average price of $177.48 and a 200 day moving average price of $169.60. The company has a current ratio of 4.54, a quick ratio of 4.35 and a debt-to-equity ratio of 0.03.

BeiGene (NASDAQ:BGNEGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($5.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.23) by ($1.33). BeiGene had a negative return on equity of 38.58% and a negative net margin of 187.65%. The firm had revenue of $341.57 million for the quarter, compared to analyst estimates of $297.28 million. Sell-side analysts anticipate that BeiGene, Ltd. will post -17.02 earnings per share for the current year.

Insiders Place Their Bets

In other BeiGene news, insider Lai Wang sold 445 shares of the stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $139.40, for a total transaction of $62,033.00. Following the completion of the transaction, the insider now owns 723 shares of the company’s stock, valued at $100,786.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other BeiGene news, CFO Julia Aijun Wang sold 295 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $158.50, for a total transaction of $46,757.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Lai Wang sold 445 shares of the firm’s stock in a transaction that occurred on Friday, June 17th. The shares were sold at an average price of $139.40, for a total transaction of $62,033.00. Following the completion of the transaction, the insider now directly owns 723 shares of the company’s stock, valued at approximately $100,786.20. The disclosure for this sale can be found here. Insiders sold a total of 3,670 shares of company stock valued at $546,229 over the last 90 days. 7.50% of the stock is owned by company insiders.

Analyst Ratings Changes

BGNE has been the subject of a number of recent research reports. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $296.00 target price on shares of BeiGene in a research report on Tuesday, August 9th. Morgan Stanley reduced their target price on shares of BeiGene from $300.00 to $293.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Finally, StockNews.com upgraded shares of BeiGene from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $299.25.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Further Reading

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.